Concepedia

Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study

Elizabeth M. Swisher, Carol Aghajanian, David M. O’Malley, Gini F. Fleming, Scott H. Kaufmann, Douglas A. Levine, Michael J. Birrer, Kathleen N. Moore, Nick M. Spirtos, Mark S. Shahin,

Gynecologic Oncology · 2021 · 38 citations · 24 references

DOIFull text

Open access

Abstract

These results potentially broaden opportunities for PARPi utilization among patients who would not qualify for frontline PARPi maintenance based on other trials.

References

24

Structural Model Evaluation and Modification: An Interval Estimation Approach

James H. Steiger · Multivariate Behavioral Research · 1990 · 7.3K citations

, , +9

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.5K citations

, , +7

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia et al. · New England Journal of Medicine · 2018 · 2.7K citations · Full text

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt et al. · New England Journal of Medicine · 2016 · 2.4K citations · Full text

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Antonio González-Martı́n, Bhavana Pothuri, Ignace Vergote et al. · New England Journal of Medicine · 2019 · 2.1K citations · Full text